EU6 Stock Overview
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
PDS Biotechnology Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.60 |
| 52 Week High | US$9.15 |
| 52 Week Low | US$2.60 |
| Beta | 1.71 |
| 1 Month Change | -42.86% |
| 3 Month Change | -29.73% |
| 1 Year Change | -57.93% |
| 3 Year Change | -35.69% |
| 5 Year Change | -49.77% |
| Change since IPO | -57.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| EU6 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -12.5% | -4.3% | -2.5% |
| 1Y | -57.9% | -19.4% | -0.4% |
Return vs Industry: EU6 underperformed the German Biotechs industry which returned -15.8% over the past year.
Return vs Market: EU6 underperformed the German Market which returned 1% over the past year.
Price Volatility
| EU6 volatility | |
|---|---|
| EU6 Average Weekly Movement | 12.8% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: EU6's share price has been volatile over the past 3 months.
Volatility Over Time: EU6's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 25 | Frank Bedu-Addo | www.pdsbiotech.com |
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company’s lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers.
PDS Biotechnology Corporation Fundamentals Summary
| EU6 fundamental statistics | |
|---|---|
| Market cap | €96.25m |
| Earnings (TTM) | -€40.25m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.3x
P/E RatioIs EU6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EU6 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$42.94m |
| Earnings | -US$42.94m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.17 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 90.6% |
How did EU6 perform over the long term?
See historical performance and comparison